MLchartDataset catalogue

gridegalutamide

Term · Oncology and biomedicine · MLC-T-ONC-014039

An orally bioavailable androgen receptor (AR) degrader, with potential antineoplastic activity. Upon administration, gridegalutamide causes degradation of AR, prevents AR-mediated signaling and inhibits the proliferation of AR-overexpressing tumor cells. AR plays a key role in tumor cell proliferation in castration-resistant prostate cancer (CRPC).

Table 1. Record
IdentifierMLC-T-ONC-014039
FieldOncology and biomedicine
SynonymsAR degrader CC-94676; Androgen Receptor Degrader CC-94676
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-014039",
  "term": "gridegalutamide",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable androgen receptor (AR) degrader, with potential antineoplastic activity. Upon administration, gridegalutamide causes degradation of AR, prevents AR-mediated signaling and inhibits the proliferation of AR-overexpressing tumor cells. AR plays a key role in tumor cell proliferation in castration-resistant prostate cancer (CRPC).",
  "synonyms": [
    "AR degrader CC-94676",
    "Androgen Receptor Degrader CC-94676"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/gridegalutamide/"
}

Record 8,201 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.